Find information about Interpharma and its members here: from social media to press releases and stories. Scroll down for the press archive. Click through the latest posts from our members and partners. Furthermore, you can view facts and figures about the Swiss healthcare and pharmaceutical landscape in our datacenter.
read more
The pharmaceutical industry in Switzerland will also need attractive framework conditions in future, including legal certainty, open export markets and the availability of labour.
In Switzerland, the median time from first submission by a pharmaceutical company to availability of a medicinal product to patients is almost 650 days.
In future, patients should have access to innovative medicines on the day the product is authorised by Swissmedic («Day 0»).
People in Switzerland benefit from access to high-quality healthcare provision. However, there is still a need for action and improvement in various areas.
Every franc of value that the pharmaceutical industry creates generates an additional 73 cents of value in other sectors of Swiss industry.
Interpharma members currently invest around CHF 6.5 billion a year in research and development in Switzerland.
The gross value added by the pharmaceutical industry in Switzerland was 9.3% of GDP in 2018.
In just a few years, Switzerland has fallen from first to fifth place in the Global Competitiveness Index (2019).
The pharmaceutical industry's share of total exports in Switzerland was 38% in 2018.
Pharmacological and technological innovations will bring about a fundamental change in the way medicines are developed and used, enabling new approaches to be adopted in research.
Accounting for 46% of all exports, the EU was the Swiss pharmaceutical industry's biggest trading partner in 2019.
is the direct contribution of the pharmaceutical sector to the gross domestic product (GDP), making it one of Switzerland's most significant private-industry sectors.
of women in the workforce, supplemented by efforts to extend parental leave, help the industry become a leader in reconciling work and family life.
of those surveyed in health monitor 2019 rated the quality of healthcare in Switzerland as good.
Medicines in Switzerland account for just 13% of healthcare costs.
It takes an average of 13 years before a medicine with a new active substance comes to market.
The 23 member companies of Interpharma together account for over 90% of the market share in patented medicines in Switzerland.
Our mission is to ensure that patients in Switzerland receive access to innovative medicines and therapies as quickly as possible.
The chances of surviving a heart attack today are five times greater than in 1960.
are numerous diseases that often used to prove serious or fatal for patients, for example hepatitis C, thanks to innovative medicines.
Between 1990 and 2015 the mortality rate for breast cancer fell by 30%.
The chances of a cure for cancer in children have risen from 40% to 80% between 1973 and 2012.
years is the increase in life expectancy in Switzerland compared to 50 years ago. Innovative drugs have made a crucial contribution to this increase.
people work in the pharmaceutical industry in Switzerland. A further 200,000 jobs at least also depend indirectly on the sector.
of all exports, the EU was the Swiss pharmaceutical industry's biggest trading partner in 2019.
francs is the total of direct and indirect value added contributed by the pharmaceutical production and research activities. This corresponds to 9.3% of Switzerland's total economic output.
lower is the mortality rate for breast cancer compared to 25 years ago. The chances of a cure for cancer in children has almost doubled in 40 years.
is the pharmaceutical industry's share of Swiss goods exports, making it the country's most important export sector by far.
francs are invested by the members of Interpharma each year in research & development in Switzerland. As a result, for every franc earned from sales in Switzerland, almost two are reinvested.
Interpharma, the association of Switzerland’s research-based pharmaceutical industry, was founded in Basel in 1933.
Interpharma informs the public about issues that are important to the research-based pharmaceutical industry in Switzerland, including the pharma market in Switzerland, healthcare and biomedical research.
Information on our key figures and activities in the financial year 2023
read more
Introducing Interpharma
read more
More about the tasks and overriding aims of Interpharma
read more
Contact us
read more
Latest information and media contacts for media representatives
read more
Download
